Neurotransmitter receptor alterations in Parkinson's disease.
about
Visual and auditory evoked responses in patients with Parkinson's disease.The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's diseaseAsymmetrical lateral ventricular enlargement in Parkinson's disease.Human serum Cohn fraction IV (alpha-globulin [correction of globin] enriched) inhibits ligand binding at neurotransmitter receptors in human brainProof of principle: Transformation approach alters caudate nucleus volume and structure-function associations.The characteristic Ag(core)Au(shell) nanoparticles as SERS substrates in detecting dopamine molecules at various pH ranges.Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humansComparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's diseaseThe nucleus basalis of Meynert in neurological dementing disease: a review.Serotonin in involuntary movement disorders.Upregulation of striatal dopamine receptors and improvement of motor performance in senescence.Altered striatal dopaminergic and cholinergic reciprocal inhibitory control and motor behavioral decrements in senescence.Responses of the mouse vas deferens to dopamine and some related drugs [proceedings]Inter-relationships between behavioural and neurochemical indices of supersensitivity in dopaminergic neurones [proceedings]Neurotransmitter deficits in Alzheimer's disease: criteria for significance.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain.Postmortem changes in rat brain: studies on membrane-bound enzymes and receptors.Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.Pitfalls in membrane binding sites studies in post-mortem human brain.Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease.Effect of postmortem factors on muscarinic receptor subtypes in rat brain.Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson's disease.Transmembrane signalling systems in the brain of patients with Parkinson's disease.Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation.Early undernutrition and [3H]gamma-aminobutyric acid binding in rat brain.Effects of postmortem delay and temperature on neurotransmitter receptor binding in a rat model of the human autopsy process.In vivo kinetics of [18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding.Postmortem changes in binding to the muscarinic receptor from human cerebral cortex.Age-correlated loss of dopaminergic binding sites in human basal ganglia.Alterations in neurotransmitter receptor binding in discrete areas of the copper-deficient rat brain.
P2860
Q30496029-28C10704-B20D-48E9-A4A9-FB65429E8DC8Q33591306-EF404960-D322-4905-B332-2B28650FD0E9Q34012649-81B427E1-FAF9-4EE4-8AEC-D88D385269DCQ35612951-F71E2FEB-BBF8-456F-9A4C-7B522066C7B0Q35634769-6CE2299F-F9AD-4008-B57A-40B5477104CAQ36010384-E08D83C9-A3A8-49F1-BF2B-A219EEB581C7Q36666227-CC14DD29-D09F-4648-9127-390AE62C58C3Q36947508-EECDE29C-FD9F-48BD-A9D9-5FB9DD0E5A18Q39483754-951A030F-2CB0-4DFD-AF91-4E2A45EB14EEQ39551919-3CFE524C-933D-4117-82C9-2B4145BCA88DQ39639350-F1DBB059-2A3B-4EBE-9C57-7D8D1DB2A876Q39644224-3ADDD620-EB82-4FA8-B1C6-9C6DD318196EQ40055821-8D76200E-1EA3-41DC-A2AC-F13000E83778Q40057598-1D741E89-50C2-46C7-8C8C-8C6553B00612Q40089993-9E5E9E02-AA6F-43B4-AB65-FAED6660D794Q41846717-FA5A4C41-133A-425E-A046-E747FD5A5F8DQ41962167-898E8036-B730-48F4-902A-52A9DF615831Q42206401-F41DC4EB-AE4D-4C72-B787-DCD4F51D4030Q42582910-701FECDB-D1CE-4BA8-8C0D-6836F18B4EE8Q45765813-1059AA63-A93B-478B-8AA2-6A76EF3ED6DAQ48203128-F5F19388-921A-4353-97FA-218618476D1CQ48225315-60C83123-C7E7-4543-8920-01CF83F1D2A5Q48238959-8201D729-F989-4B66-899D-3457E55F5CCEQ48316986-F1F594DF-2571-44EC-A0C3-D0B211010ADDQ48383210-F2C3E57C-970B-4F78-9752-B0EA7A125DCAQ48632475-2C6C03FE-DCC8-458F-AB13-D71D6B9DBA54Q48640809-71F6CC22-27DF-42AB-8CCC-F55307791BF1Q48644876-991630BC-0630-445E-8F14-AAD693E9F9CBQ48784626-B54B8A52-0207-4234-BEE7-4C7549C9A6A9Q48866234-5EB8F113-49AA-4B4E-9725-0BB9A48DC642Q49012303-EBC78CB9-65D6-43A6-ADA0-DD6AB979DA4D
P2860
Neurotransmitter receptor alterations in Parkinson's disease.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Neurotransmitter receptor alterations in Parkinson's disease.
@en
type
label
Neurotransmitter receptor alterations in Parkinson's disease.
@en
prefLabel
Neurotransmitter receptor alterations in Parkinson's disease.
@en
P2093
P1433
P1476
Neurotransmitter receptor alterations in Parkinson's disease.
@en
P2093
Reisine TD
Yamamura HI
P304
P356
10.1016/0024-3205(77)90514-8
P407
P577
1977-08-01T00:00:00Z